<DOC>
	<DOCNO>NCT00440778</DOCNO>
	<brief_summary>HYPOTHESES 1 . Bolus administration total abciximab dose provide superior maximal mean platelet aggregation inhibition ( PAI ) compare standard bolus ( 0.25 mg/kg ) administration . 2 . Total dose abciximab give single bolus effective bolus ( 0.25 mg/kg ) + 12 hr infusion term acute mid-term angiographic clinical result . 3 . Intracoronary ( ic ) abciximab administration effective intravenous ( iv ) route administration term acute mid-term angiographic clinical result . 4 . There relationship PAI angiographic perfusion score . 5 . Routine use sirolimus-eluting stent ( Cypher , Cordis ) primary-PCI associate low rate target vessel revascularization complication . 6 . Cardiac MRI early late primary-PCI provide detailed information myocardial injury irreversible necrosis , correlate angiographic perfusion score . 7 . After uncomplicated trans-radial PCI , patient retransferred early referring center .</brief_summary>
	<brief_title>A Randomized Trial Early Discharge After Trans-radial Stenting Coronary Arteries Acute MI</brief_title>
	<detailed_description>OBJECTIVES AND END-POINTS The objective present study ass benefit safety 1 ) single bolus abciximab ( 100 % dose ) compare standard bolus ( ca 80 % total dose ) + 12h infusion ( ca 20 % total dose ) , 2 ) intracoronary abciximab bolus administration compare intravenous route abciximab administration primary PCI . The primary PLATELETS end-points percentage patient ≥ 95 % platelet aggregation inhibition 10 minute abciximab bolus ( MAX ) mean platelet aggregation inhibition 10 minute abciximab bolus ( MEAN ) . The secondary CLINICAL end-points study : - The composite death , stroke , repeat myocardial infarction , urgent target vessel revascularization major bleeding 30 day follow primary PCI . - The composite cardiovascular death , repeat myocardial infarction repeat target vessel revascularization 6-months follow-up . The secondary ANGIOGRAPHIC end-points study : - The proportion patient myocardial blush grade 2-3 TIMI 3 score end PCI culprit vessel . - The restenosis rate ( diameter stenosis ≥ 50 % ) late loss culprit vessel 6-months follow-up . Other exploratory end-points feasibility safety early transfer refer hospital uncomplicated primary PCI , cardiac MRI measurement platelet aggregation inhibition 6h post-PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patient acute myocardial infarction eligible primary PCI within 6 h symptom : patient must prolong , continuous ( last least 20 minute ) sign symptom ischemia eliminate nitrate onset within 6 h randomization , one following : STsegment elevation ≥ 2 mm 2 contiguous precordial ECG lead ( anterior infarction ) STsegment depression ≥ 2 mm V1 , V2 V2 , V3 reciprocal 1 mm STelevation II , augment unipolar foot ( left leg ) lead ( AVF ) , V6 ( true posterior infarction ) STsegment elevation ≥ 1 mm 2 contiguous limb ECG lead ( infarction ) New presumably new leave bundle branch block ( LBBB ) Patient must &gt; 18 year age . Patient treat interventional cardiologist agree randomization . Patient inform randomization process sign inform consent . Diagnostic therapeutic intervention perform transradial/ulnar artery approach . The culprit lesion identify native coronary vessel , suitable primary PCI stent implantation . Patient receive thrombolytic therapy ( within last 4 week ) refer rescue PCI Concurrent participation investigational study Femoral sheath ( artery ) Intolerance allergy ASA , clopidogrel ticlopidine preclude treatment least 12 month Any significant blood dyscrasia , diathesis INR &gt; 2.0 Any clinical contraindication abciximab ( ReoPro® ) administration i.e . know structural intracranial lesion , thrombocytopenia &lt; 100,000 , active recent bleed hemoglobin level know &lt; 10 g/dl . Any glycoprotein IIbIIIa inhibitor use previous 30 day Uncontrolled high blood pressure i.e . systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg . Life expectancy le 6 month owe noncardiac cause Infarction cause instent thrombosis restenosis Cardiogenic shock evident randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Coronary artery stenting</keyword>
	<keyword>Trans-radial</keyword>
	<keyword>Intracoronary</keyword>
</DOC>